A. Sezer Et Al. , "Cemiplimab, a Human PD-1 Monoclonal Antibody, Versus Chemotherapy in First-Line Treatment of Advanced NSCLC with PD-L1 >= 50%," JOURNAL OF THORACIC ONCOLOGY , vol.14, no.10, 2019
Sezer, A. Et Al. 2019. Cemiplimab, a Human PD-1 Monoclonal Antibody, Versus Chemotherapy in First-Line Treatment of Advanced NSCLC with PD-L1 >= 50%. JOURNAL OF THORACIC ONCOLOGY , vol.14, no.10 .
Sezer, A., Gogishvili, M., Bentsion, D., Kilickap, S., Lowczak, A., Gumus, M., ... Gladkov, O.(2019). Cemiplimab, a Human PD-1 Monoclonal Antibody, Versus Chemotherapy in First-Line Treatment of Advanced NSCLC with PD-L1 >= 50%. JOURNAL OF THORACIC ONCOLOGY , vol.14, no.10.
Sezer, A. Et Al. "Cemiplimab, a Human PD-1 Monoclonal Antibody, Versus Chemotherapy in First-Line Treatment of Advanced NSCLC with PD-L1 >= 50%," JOURNAL OF THORACIC ONCOLOGY , vol.14, no.10, 2019
Sezer, A. Et Al. "Cemiplimab, a Human PD-1 Monoclonal Antibody, Versus Chemotherapy in First-Line Treatment of Advanced NSCLC with PD-L1 >= 50%." JOURNAL OF THORACIC ONCOLOGY , vol.14, no.10, 2019
Sezer, A. Et Al. (2019) . "Cemiplimab, a Human PD-1 Monoclonal Antibody, Versus Chemotherapy in First-Line Treatment of Advanced NSCLC with PD-L1 >= 50%." JOURNAL OF THORACIC ONCOLOGY , vol.14, no.10.
@article{article, author={A. Sezer Et Al. }, title={Cemiplimab, a Human PD-1 Monoclonal Antibody, Versus Chemotherapy in First-Line Treatment of Advanced NSCLC with PD-L1 >= 50%}, journal={JOURNAL OF THORACIC ONCOLOGY}, year=2019}